J.W. Cole Advisors, Inc. Esperion Therapeutics, Inc. Transaction History
J.W. Cole Advisors, Inc.
- $4.58 Billion
- Q2 2025
A detailed history of J.W. Cole Advisors, Inc. transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, J.W. Cole Advisors, Inc. holds 43,900 shares of ESPR stock, worth $124,676. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,900
Previous 43,900
-0.0%
Holding current value
$124,676
Previous $63,000
31.75%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ESPR
# of Institutions
185Shares Held
109MCall Options Held
139KPut Options Held
604K-
Black Rock Inc. New York, NY14MShares$39.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$33.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$29.4 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$28.3 Million0.18% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$19 Million4.26% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $189M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...